Latest News - AMD

Tuesday, September 19, 2017 | Clinical Trials, Retina, AMD, GrayBug

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Monday, September 11, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech's Lampalizumab Fails Phase 3 Study for Geographic Atrophy

Genentech announced that the primary endpoint has not been met in Spectri, the first of two phase 3 studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the trea…

Read the full story

Thursday, August 24, 2017 | Clinical Trials, Retina, AMD

Apellis Pharmaceuticals Announces APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy

Apellis Pharmaceuticals announced that its complement C3 inhibitor, APL-2, met its primary endpoint in a phase 2 clinical trial (FILLY) in patients with geographic atrophy (GA) associated with age-rel…

Read the full story

Wednesday, August 16, 2017 | Retina, AMD, Opthea

New Anti-VEGF Drug Promising for Wet Macular Degeneration

A new antivascular endothelial growth-factor (VEGF) drug, OPT-302 (Opthea), appears to be safe and shows signs of effectiveness in the treatment of neovascular age-related macular degeneration, new re…

Read the full story

Monday, August 14, 2017 | Retina, AMD, BioTime

BioTime Announces $2 Million Grant for Further Development of OpRegen for Dry AMD

BioTime has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (IIA) to fund the continued development of OpRege…

Read the full story

Monday, August 14, 2017 | Clinical Trials, Retina, AMD, Ophthotech

Ophthotech's Fovista Fails Third Phase 3 Trial in Wet AMD

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its phase 3 clinical trial investigating the superiority of Fovis…

Read the full story

Monday, July 31, 2017 | Partnerships, Akorn Pharmaceuticals, AMD

Aerie Pharmaceuticals Enters into Collaboration with DSM Focused on Technology to Potentially Deliver Aerie Compounds to Treat Retinal Diseases

Aerie Pharmaceuticals announced that it has entered into a collaborative research, development, and license agreement with DSM. The research collaboration agreement includes an option to license DSM&r…

Read the full story

Friday, July 28, 2017 | Retina, AMD

NEI 3-D Retina Organoid Challenge (3-D ROC)

The National Eye Institute (NEI), part of the National Institutes of Health, is seeking ideas for how to develop advances in vitro 3-D human retina organoid models. The goal of the challenge is to tur…

Read the full story

Wednesday, July 26, 2017 | Clinical Trials, Earnings & Financials, AMD, Ophthotech

Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases

Ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for…

Read the full story

Tuesday, July 25, 2017 | Partnerships, AMD, Foundation Fighting Blindness

4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

4D Molecular Therapeutics (4DMT), a provider of adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s large…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, AMD, BioTime

Data From BioTime’s Phase 1/2a OpRegen Trial to be Presented at the 2017 AAO Annual Meeting

BioTime announced that an abstract related to the company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being …

Read the full story

Friday, July 14, 2017 | Clinical Trials, AMD

Spark Therapeutics Announces Publication of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec

Gene therapy company Spark Therapeutics announced that The Lancet has published phase 3 clinical trial data of voretigene neparvovec, an investigational, potential one-time gene therapy candidate for …

Read the full story

Friday, June 30, 2017 | Medical Studies, AMD

An Eye to Health: Diet and Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a leading cause of vision loss in the developed world, with advanced AMD affecting approximately 2 million people in the United States.[1,2] AMD is characteri…

Read the full story

Friday, June 30, 2017 | Retina, AMD

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

NightstaRx announced the completion of a $45 million Series C financing transaction, the proceeds of which will be used for the upcoming phase 3 trial for Nightstar’s lead product candidate, NSR…

Read the full story

Thursday, June 29, 2017 | Medical Studies, Retina, AMD

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms

Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study. "Blood cancers, which most recent…

Read the full story
Load More